胃复春胶囊辅助西药治疗脾胃虚弱证慢性浅表性胃炎疗效观察及对血清胃泌素的影响
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R573.3+1

基金项目:


Clinical Effect of Weifuchun Capsules in Adjuvant Treatment of Chronic Superficial Gastritis with Spleen-Stomach Weakness Syndrome and Its Effects on Serum Gastrin
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察胃复春胶囊辅助西药治疗脾胃虚弱证慢性浅表性胃炎(CSG) 的疗效及其对血清胃泌 素(GAS) 的影响。方法:回顾性分析128 例脾胃虚弱证CSG 患者,根据治疗方式的不同分为对照组和观察 组各64 例。对照组给予奥美拉唑肠溶胶囊口服,观察组在对照组的基础上加用胃复春胶囊口服。比较2 组临 床疗效、幽门螺杆菌(Hp) 阳性率、不良反应以及治疗前后中医证候评分、血清胃泌素水平。结果:观察组 总有效率为93.75%,对照组为81.25%,2 组比较,差异有统计学意义(P<0.05)。治疗前,2 组胃脘痞滞、隐 痛、纳呆少食、食后胀闷、四肢乏力等中医证候评分比较,差异无统计学意义(P>0.05);治疗后,2 组上述 各项中医证候评分均较治疗前降低(P<0.05),且观察组各项证候评分均低于对照组(P<0.05)。治疗前, 2 组Hp 阳性率比较,差异无统计学意义(P>0.05);治疗后,2 组Hp 阳性率均较治疗前下降(P<0.05),且 观察组Hp 阳性率低于对照组(P<0.05)。治疗前,2 组血清GAS 水平比较,差异无统计学意义(P>0.05); 治疗后,2 组血清GAS 水平均较治疗前升高(P<0.05),且观察组GAS 水平高于对照组(P<0.05)。观察组 不良反应发生率为7.81%,对照组为18.75%,2 组比较,差异有统计学意义(P<0.05)。结论:胃复春胶囊辅 助西药治疗脾胃虚弱证CSG 可提高临床疗效,改善血清GAS 水平及中医证候,降低Hp 阳性率及不良反应发 生率。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Weifuchun Capsules in adjuvant treatment of chronic superficial gastritis (CSG) with spleen- stomach weakness syndrome and its effect on the level of serum gastrin (GAS). Methods:A total of 128 cases with CSG with spleen-stomach weakness syndrome were retrospectively studied and divided into the control group and the observation group according to different treatment methods,with 64 cases in each group. The control group was treated with Omeprazole Enteric- soluble Capsules orally, and the observation group was additionally given Weifuchun Capsules based on the treatment of the control group. The clinical effects,positive rates of helicobacter pylori (Hp), the incidence of adverse reactions,traditional Chinese medicine syndrome scores as well as the levels of serum GAS in the two groups were compared. Results: The total effective rate was 93.75% in the observation group,higher than that of 81.25% in the control group,the difference being significant (P< 0.05). Before treatment, there was no significant difference being found in the comparisons of TCM syndrome scores of stuffiness and stagnation in the stomach duct, dull pain, torpid intake and poor appetite, abdominal distension and oppression after eating, lack of strength in limbs between the two groups (P>0.05); after treatment, the five scores above in the two groups were decreased when compared with those before treatment (P<0.05),and the five scores in the observation group were lower than those in the control group (P<0.05). Before treatment,there was no significant difference being found in the comparison of Hp positive rates between the two groups (P>0.05);after treatment,the Hp positive rates in both groups were decreased when compared with those before treatment (P<0.05),and the Hp positive rate in the observation group was lower than that in the control group (P<0.05). Before treatment, there was no significant difference being found when comparing the levels of serum GSA between the two groups (P>0.05); after treatment, the levels of serum GSA in both groups were increased when compared with those before treatment (P<0.05),and the level of serum GSA in the observation group was higher than that in the control group (P<0.05). The incidence of adverse reactions was 7.81% in the observation group, lower than that of 18.75% in the control group, the difference being significant (P< 0.05). Conclusion:Weifuchun Capsules in adjuvant treatment of western medicine for CSG with spleenstomach weakness syndrome can increase the clinical effect,improve the level of serum GSA and the TCM syndrome,and decrease the Hp positive rate and the incidence of adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

赵书红,马永亮,徐健,陈思桢.胃复春胶囊辅助西药治疗脾胃虚弱证慢性浅表性胃炎疗效观察及对血清胃泌素的影响[J].新中医,2023,55(6):50-53

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-03-28
  • 出版日期: